GeneFerm Biotechnology Co Ltd (1796) - Net Assets
Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) has net assets worth NT$794.03 Million TWD (≈ $25.02 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.25 Billion ≈ $39.29 Million USD) and total liabilities (NT$453.10 Million ≈ $14.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GeneFerm Biotechnology Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$794.03 Million |
| % of Total Assets | 63.67% |
| Annual Growth Rate | 14.0% |
| 5-Year Change | 98.94% |
| 10-Year Change | N/A |
| Growth Volatility | 58.19 |
GeneFerm Biotechnology Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. See 1796 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual net assets of GeneFerm Biotechnology Co Ltd from 2017 to 2024. For live valuation and market cap data, see 1796 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$788.18 Million ≈ $24.83 Million |
-11.72% |
| 2023-12-31 | NT$892.84 Million ≈ $28.13 Million |
+7.47% |
| 2022-12-31 | NT$830.77 Million ≈ $26.17 Million |
+11.12% |
| 2021-12-31 | NT$747.66 Million ≈ $23.56 Million |
+88.71% |
| 2020-12-31 | NT$396.19 Million ≈ $12.48 Million |
-58.49% |
| 2019-12-31 | NT$954.50 Million ≈ $30.07 Million |
+129.16% |
| 2018-12-31 | NT$416.51 Million ≈ $13.12 Million |
+32.25% |
| 2017-12-31 | NT$314.95 Million ≈ $9.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GeneFerm Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$39.18 Million | 4.97% |
| Other Components | NT$749.00 Million | 95.03% |
| Total Equity | NT$788.18 Million | 100.00% |
GeneFerm Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of GeneFerm Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Texton Property Fund Ltd
JSE:TEX
|
$44.36 Million |
|
Tree Island Steel Ltd.
TO:TSL
|
$44.36 Million |
|
Canlan Ice Sports Corp.
TO:ICE
|
$44.38 Million |
|
GSD Denizcilik Gayrimenkul Insaat Sanayi ve Ticaret AS
IS:GSDDE
|
$44.38 Million |
|
Corby Spirit and Wine Limited
TO:CSW-B
|
$44.33 Million |
|
Mospec Semiconductor Corp
TW:2434
|
$44.30 Million |
|
Groupe Partouche SA
PA:PAR
|
$44.29 Million |
|
Star Comgistic Capital Co Ltd
TW:4930
|
$44.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneFerm Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 892,837,000 to 788,184,000, a change of -104,653,000 (-11.7%).
- Net loss of 22,528,000 reduced equity.
- Dividend payments of 82,920,000 reduced retained earnings.
- Other comprehensive income decreased equity by 27,692,000.
- Other factors increased equity by 28,487,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-22.53 Million | -2.86% |
| Dividends Paid | NT$82.92 Million | -10.52% |
| Other Comprehensive Income | NT$-27.69 Million | -3.51% |
| Other Changes | NT$28.49 Million | +3.61% |
| Total Change | NT$- | -11.72% |
Book Value vs Market Value Analysis
This analysis compares GeneFerm Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.69x to 1.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$12.62 | NT$33.95 | x |
| 2018-12-31 | NT$14.99 | NT$33.95 | x |
| 2019-12-31 | NT$13.99 | NT$33.95 | x |
| 2020-12-31 | NT$14.20 | NT$33.95 | x |
| 2021-12-31 | NT$16.16 | NT$33.95 | x |
| 2022-12-31 | NT$19.51 | NT$33.95 | x |
| 2023-12-31 | NT$21.46 | NT$33.95 | x |
| 2024-12-31 | NT$19.01 | NT$33.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneFerm Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.32%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.45x
- Recent ROE (-2.86%) is below the historical average (4.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 8.96% | 8.07% | 0.69x | 1.62x | NT$-3.26 Million |
| 2018 | 2.48% | 2.89% | 0.64x | 1.34x | NT$-31.34 Million |
| 2019 | -7.07% | -8.39% | 0.33x | 2.57x | NT$-66.52 Million |
| 2020 | 1.14% | 1.23% | 0.37x | 2.48x | NT$-35.09 Million |
| 2021 | 7.68% | 10.99% | 0.40x | 1.76x | NT$-17.35 Million |
| 2022 | 11.25% | 14.74% | 0.53x | 1.43x | NT$10.38 Million |
| 2023 | 13.96% | 15.70% | 0.68x | 1.32x | NT$35.34 Million |
| 2024 | -2.86% | -4.32% | 0.45x | 1.45x | NT$-101.35 Million |
Industry Comparison
This section compares GeneFerm Biotechnology Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,325,253,889
- Average return on equity (ROE) among peers: 5.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneFerm Biotechnology Co Ltd (1796) | NT$794.03 Million | 8.96% | 0.57x | $44.35 Million |
| Grape King Bio Ltd (1707) | $1.74 Billion | 9.43% | 0.48x | $462.98 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $3.12 Billion | 7.90% | 0.56x | $352.43 Million |
| Maywufa Co Ltd (1731) | $1.47 Billion | 5.23% | 0.78x | $90.87 Million |
| ScinoPharm Taiwan Ltd (1789) | $8.56 Billion | 11.21% | 0.11x | $499.50 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $1.49 Billion | 0.80% | 0.34x | $1.58 Billion |
| LIWANLI Innovation Co Ltd (3054) | $1.51 Billion | 4.15% | 0.15x | $172.02 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $478.34 Million |
| TTY Biopharm Co Ltd (4105) | $5.77 Billion | 14.42% | 0.61x | $577.35 Million |
| Phytohealth Corp (4108) | $1.56 Billion | -10.88% | 0.06x | $75.40 Million |
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more